Immunic to Participate in Key Conferences Throughout November

Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm specializing in orally administered therapies for inflammatory and autoimmune diseases, will be active in several conferences in November. The company has outlined its participation in industry, scientific, and investor events, aiming to showcase its advancements and engage with stakeholders.

From November 4 to 6, Immunic's management and business teams will attend BIO-Europe in Stockholm, Sweden. The focus is on partnering activities. Sara Elhag, Ph.D., will present clinical trial data at the Immuno-Mediated Diseases Symposium in Florence, Italy on November 8 and 9.

In London, from November 19 to 21, Immunic will conduct one-on-one meetings in conjunction with the Jefferies London Healthcare Conference. The month concludes with Daniel Vitt, Ph.D., presenting at the Virtual Investor Summit on November 21, detailing the company's developments.